Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

How I treat older patients with DLBCL in the frontline setting

Pieternella J. Lugtenburg, Pim G. N. J. Mutsaers

Blood (2023) 141 (21): 2566–2575.

https://doi.org/10.1182/blood.2020008239

Published: 2023

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-133820

Published: 2020

Journal Articles

18 f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients

Jakoba J Eertink, MSc, Tim van de Brug, PhD, Sanne E Wiegers, MSc, Gerben J.C. Zwezerijnen, MD, Elisabeth Pfaehler, MSc, Pieternella J. Lugtenburg, MD PhD, Bronno van der Holt, PhD, Henrica C.W. de Vet, PhD, Otto S Hoekstra, MD PhD, Ronald Boellaard, PhD, Josée M Zijlstra, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-140245

Published: 2020

Journal Articles

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Max Topp, MD, Tom Van Meerten, MD PhD, Roch Houot, MD PhD, Monique C. Minnema, Noel Milpied, MD, Pieternella J. Lugtenburg, MD PhD, Catherine Thieblemont, MD PhD, Martin Wermke, MD, Kevin Song, MD, Irit Avivi, MD, John Kuruvilla, MD, Ulrich Dührsen, Prof, MD PhD, Rachel Chu, PhD, Lianqing Zheng, PhD, Vicki Plaks, PhD, Anne Kerber, MD, Marie Jose' Kersten, MD PhD

Blood (2019) 134 (Supplement_1): 243.

https://doi.org/10.1182/blood-2019-126081

Published: 2019

Journal Articles

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Blood (2019) 133 (18): 1964–1976.

https://doi.org/10.1182/blood-2018-11-880526

Published: 2019

Includes: Supplemental data

Journal Articles

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Blood (2018) 132 (Supplement 1): 782.

https://doi.org/10.1182/blood-2018-99-118519

Published: 2018

Journal Articles

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines

Frederika A. van Nimwegen, Georgios Ntentas, Sarah C. Darby, Michael Schaapveld, Michael Hauptmann, Pieternella J. Lugtenburg, Cecile P. M. Janus, Laurien Daniels, Flora E. van Leeuwen, David J. Cutter, Berthe M. P. Aleman

Blood (2017) 129 (16): 2257–2265.

https://doi.org/10.1182/blood-2016-09-740332

Published: 2017

Includes: Supplemental data

Journal Articles

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Andrew D. Zelenetz, MD PhD, Gilles A. Salles, Kylie D Mason, MBBS, FRACP, FRCPA, PhD, Carla Casulo, MD, Steven Le Gouill, MD PhD, Laurie H Sehn, MD, Hervé Tilly, MD PhD, Guillaume Cartron, MD PhD, Martine ED Chamuleau, MD, Andre Goy, MD, Constantine S. Tam, MD, Pieternella J Lugtenburg, MD PhD, Rebecca Elstrom, MD, Thalia Farazi, MD PhD, Juan Liu, Edith Szafer-Glusman, PhD, Mehrdad Mobasher, MD, Franck Morschhauser

Blood (2016) 128 (22): 3032.

https://doi.org/10.1182/blood.V128.22.3032.3032

Published: 2016

Journal Articles

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah, MD, Gregory Dueck, John Gribben, Pieternella J Lugtenburg, MD PhD, Oliver Press, Gilles A. Salles, Günter Fingerle-Rowson, Federico Mattiello, Elisabeth Wassner-Fritsch, Laurie H Sehn

Blood (2016) 128 (22): 615.

https://doi.org/10.1182/blood.V128.22.615.615

Published: 2016

Journal Articles

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Jeanette K Doorduijn, MD PhD, Monique C. Minnema, MD PhD, Marie Jose Kersten, MD PhD, Pieternella J Lugtenburg, MD PhD, Martin R. Schipperus, MD PhD, Marinus van Marwijk Kooy, MD PhD, Marius MacKenzie, MD PhD, Josée M Zijlstra, MD, Henriette W Berenschot, MD, M. R Schaafsma, MD PhD, Dana A Chitu, PhD, Hanneke C. Kluin-Nelemans, MD PhD

Blood (2015) 126 (23): 339.

https://doi.org/10.1182/blood.V126.23.339.339

Published: 2015

Journal Articles

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Pieternella J Lugtenburg, MD PhD, Josée M Zijlstra, MD, Jeanette K Doorduijn, MD PhD, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD PhD, Mels Hoogendoorn, MD PhD, Henriette W Berenschot, MD, Aart Beeker, MD, Fransje Valster, MD, Harry C. Schouten, MD PhD, Marleen Luten, MSc, Henk Hofwegen, Dana A Chitu, PhD, Rolf E Brouwer, MD PhD, Gustaaf W van Imhoff, MD PhD

Blood (2015) 126 (23): 2707.

https://doi.org/10.1182/blood.V126.23.2707.2707

Published: 2015

Journal Articles

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

Bruce D. Cheson, MD, Peter C Trask, PhD MPH, John Gribben, MDDSc, Natalie Dimier, Eva Kimby, MD PhD, Pieternella J Lugtenburg, MD PhD, Catherine Thieblemont, Elisabeth Wassner Fritsch, MD, Laurie H Sehn, MD MPH

Blood (2015) 126 (23): 1532.

https://doi.org/10.1182/blood.V126.23.1532.1532

Published: 2015

Journal Articles

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

Vincent H. J. van der Velden, Patricia G. Hoogeveen, Dick de Ridder, Magdalena Schindler-van der Struijk, Menno C. van Zelm, Mathijs Sanders, Dennis Karsch, H. Berna Beverloo, King Lam, Alberto Orfao, Pieternella J. Lugtenburg, Sebastian Böttcher, Jacques J. M. van Dongen, Anton W. Langerak, Mies Kappers-Klunne, Kirsten van Lom

Blood (2014) 124 (3): 412–419.

https://doi.org/10.1182/blood-2013-10-533869

Published: 2014

Includes: Supplemental data

Journal Articles

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

Anna M. van Eggermond, Michael Schaapveld, Pieternella J. Lugtenburg, Augustinus D. G. Krol, Jan Paul de Boer, Josée M. Zijlstra, John M. M. Raemaekers, Leontien C. M. Kremer, Judith M. Roesink, Marieke W. J. Louwman, Berthe M. P. Aleman, Flora E. van Leeuwen

Blood (2014) 124 (3): 319–327.

https://doi.org/10.1182/blood-2013-10-532184

Published: 2014

Includes: Supplemental data

Journal Articles

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Pieternella J Lugtenburg, MD, PhD, Josée M Zijlstra, MD, PhD, Jeanette K Doorduijn, Lara H Böhmer, MD, Marinus van Marwijk Kooy, MD, PhD, Mels Hoogendoorn, MD, PhD, Henriette W Berenschot, MD, PhD, Aart Beeker, MD, Fransje A Valster, MD, Harry C Schouten, MD, PhD, Marleen Luten, MSc, Dana A Chitu, Rolf E Brouwer, MD, PhD, Gustaaf W van Imhoff, MD, PhD

Blood (2012) 120 (21): 2729.

https://doi.org/10.1182/blood.V120.21.2729.2729

Published: 2012

Journal Articles

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Edo Vellenga, Wim L. J. van Putten, Mars B. van 't Veer, Josée M. Zijlstra, Willem E. Fibbe, Marinus H. J. van Oers, Leo F. Verdonck, Pierre W. Wijermans, Gustaaf W. van Imhoff, Pieternella J. Lugtenburg, Peter C. Huijgens

Blood (2008) 111 (2): 537–543.

https://doi.org/10.1182/blood-2007-08-108415

Published: 2008

Includes: Supplemental data

NARROW

How I treat older patients with DLBCL in the frontline setting

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

18 f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines

Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Rituximab-Pecc Induction Followed By 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study

Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma

Rituximab-PECC Induction Followed by 90 y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or After ASCT: Preliminary Results From a Phase II HOVON Study.

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only